Table 1 A summary of CAR-T cells redirected against different antigens for the treatment of hematologic malignancies
From: Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Clinical trial identifier | Antigen | Indication | Estimated enrollment | Start date | Estimated Completion Date | Source | Conditioning regimen | Phase | Location |
|---|---|---|---|---|---|---|---|---|---|
NCT04257175 | CD19 | Acute myeloid leukemia | 10 | February 18, 2020 | December 1, 2023 | – | Flu/Cy | II/III | – |
NCT04181827 | BCMA | Relapsed and Lenalidomide-refractory multiple myeloma | 400 | June 12, 2020 | April 10, 2026 | Autologous | – | III | Multiple locations |
NCT04287660 | Multiple myeloma | 30 | October 19, 2017 | January 31, 2024 | Autologous | Clarithromycin, lenalidomide, and dexamethasone | III | China | |
NCT04340167 | CD22 | R/R acute lymphoblastic leukemia | 100 | May 1, 2020 | October 1, 2022 | Autologous | Flu/Cy | II | China |
NCT04689659 | CD7 | T-cell leukemia | 50 | February 1, 2021 | February 1, 2023 | Allogeneic | – | II | China |
NCT04351022 | CD38 | R/R acute myeloid leukemia | 20 | July 1, 2017 | December 31, 2023 | – | – | I/II | China |
NCT02259556 | CD30 | Hodgkin's lymphoma/non-Hodgkin's lymphoma | 30 | October 2014 | October 2029 | Autologous | Flu/Cy | I/II | China |
NCT03277729 | CD20 | Hematologic malignancies | 35 | December 5, 2017 | November 16, 2037 | Autologous | Flu/Cy | I/II | US |
NCT04499339 | SLAMF7 | Multiple myeloma | 38 | July 22, 2020 | March 2024 | Autologous | – | I/II | Germany |
NCT02958397 | CD33 | Myeloid malignancies | 45 | October 2016 | October 2020 | – | – | I/II | China |
NCT04230265 | CD123 | Acute myeloid leukemia and B-cell acute lymphoblastic leukemia | 45 | January 28, 2020 | April 2022 | – | Flu/Cy | I | Germany |
NCT04219163 | CLL-1 | Acute myeloid leukemia | 18 | July 9, 2020 | July 31, 2038 | Autologous | – | I | US |
NCT04712864 | CD4 | R/R T-cell lymphoma | 50 | May 2021 | September 2025 | Autologous | – | I | US |
NCT02706392 | ROR1 | Lymphoma and leukemia | 60 | March 16, 2016 | December 1, 2036 | Autologous | Flu/Cy | I | US |
NCT04690595 | BAFF-R | R/R B-cell acute lymphoblastic leukemia | 21 | April 20, 2021 | April 20, 2024 | Autologous | – | I | US |
NCT03672318 | CD138 | Multiple myeloma | 33 | January 14, 2019 | October 2032 | Autologous | Flu/Cy | I | US |
NCT03125577 | CD70 | B-cell malignancies | 100 | July 15, 2017 | December 2021 | Autologous | Flu/Cy | I/II | China |
NCT04429438 | CD79b and CD13 | B-cell lymphoma | 11 | June 1, 2020 | December 31, 2023 | – | – | I/II | China |
NCT04555551 | GPRC5D | Multiple myeloma | 36 | August 19, 2020 | August 2023 | Autologous | – | I | US |
NCT02541370 | CD133 | Acute myeloid and lymphoid leukemias | 20 | June 2015 | June 2019 | Autologous | – | I/II | China |
NCT04803929 | ILT3 | R/R acute myeloid leukemia | 25 | March 3, 2021 | March 1, 2026 | Autologous | – | Early I | China |
NCT02958384 | Lewis Y | Myeloid malignancies | 45 | October 2016 | October 2020 | Autologous | – | I/II | China |
NCT03710421 | CS1 | Multiple myeloma | 30 | February 13, 2019 | December 10, 2021 | Autologous | Flu/Cy | I/II | US |
NCT03018405 | NKG2D | Acute myeloid leukemia, multiple myeloma | 146 | December 2016 | August 2021 | Autologous | – | I/II | US and Belgium |
NCT03473457 | CD56 | R/R acute myeloid leukemia | 50 | April 1, 2018 | December 31, 2022 | – | – | NA | China |
NCT03291444 | CD117 | Acute lymphoblastic leukemia, acute myeloid leukemia | 30 | September 23, 2017 | March 1, 2022 | – | – | I | China |
NCT04429438 | CD70 | B-cell lymphoma | 11 | June 1, 2020 | December 31, 2023 | – | – | I/II | China |
NCT00881920 | Kappa light chain | Lymphoma, myeloma, and leukemia | 54 | July 2009 | July 2034 | Autologous | Flu/Cy | I | US |